(Q45119459)

9 December 2017

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial (English)

1 reference

relapsing-remitting multiple sclerosis

9 December 2017

phase I clinical trial

0 references

multiple sclerosis

0 references

0 references

1 reference

7

Emmanuelle Waubant

1 reference

9 December 2017

1

Amit Bar-Or

1 reference

9 December 2017

Peter A J Calabresi

2

1 reference

9 December 2017

Douglas Arnold

3

1 reference

9 December 2017

Clyde Markowitz

4

1 reference

9 December 2017

Stuart Shafer

5

1 reference

9 December 2017

Lloyd H Kasper

6

1 reference

9 December 2017

Suzanne Gazda

8

1 reference

9 December 2017

Robert J Fox

9

1 reference

9 December 2017

Michael Panzara

10

1 reference

9 December 2017

Neena Sarkar

11

1 reference

9 December 2017

Sunil Agarwal

12

1 reference

9 December 2017

Craig H Smith

13

1 reference

9 December 2017

1 March 2008

1 reference

9 December 2017

1 reference

9 December 2017

63

1 reference

9 December 2017

395-400

1 reference

9 December 2017

3

1 reference

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

9 December 2017

1 reference

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

21 January 2018

1 reference

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma

21 January 2018

1 reference

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ANA.21363

1 reference

9 December 2017

1 reference